Welcome to the UPF Digital Repository

Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients

Show simple item record

dc.contributor.author Córdoba Sánchez, Julián
dc.contributor.author Picola, Natàlia
dc.contributor.author Rodriguez-Vida, Alejo
dc.contributor.author Costa, Marc
dc.contributor.author Marmolejo Castañeda, David
dc.contributor.author Pérez Márquez, Meritxell
dc.contributor.author Muñoz Rodriguez, Jesús
dc.contributor.author Gaya Sopena, Josep Maria
dc.contributor.author Bravo, Alejandra
dc.contributor.author Buisan, Oscar
dc.contributor.author Servian, Pol
dc.contributor.author Suárez Novo, José Francisco
dc.contributor.author Musquera Felip, Mireia
dc.contributor.author Ribal Caparrós, Maria Jose
dc.contributor.author Alcaraz Asensio, Antonio
dc.contributor.author Vilaseca, Antoni
dc.date.accessioned 2024-10-08T06:26:16Z
dc.date.available 2024-10-08T06:26:16Z
dc.date.issued 2023
dc.identifier.citation Sánchez JC, Picola N, Rodriguez-Vida A, Costa M, Castañeda DM, Márquez MP, et al. Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients. Cancer Med. 2023 Dec;12(24):21969-77. DOI: 10.1002/cam4.6769
dc.identifier.issn 2045-7634
dc.identifier.uri http://hdl.handle.net/10230/61339
dc.description.abstract Objective: To evaluate the efficacy and safety of apalutamide prostate cancer compared to the pivotal trials patients and to identify the first subsequent therapy in a real-world setting. Methods: The study is prospective and observational based on real-world evidence, performed by different medical disciplines and eight academics centres around Barcelona, Spain. It included all patients with metastatic hormone-sensitive prostate cancer (mHSPC) and high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide from June 2018 to December 2022. Results: Of 227 patients treated with apalutamide, 10% had ECOG-PS 2, and 41% were diagnosed with new-generation imaging. In the mHSPC group (209 patients), 75 years was the median age, 53% had synchronous metastases, and 22% were M1a. In the nmCRPC (18 patients), 82 years was the median age, and 81% ≤6 months had PSA doubling time. Patients achieved PSA90 in 92% of mHSPC and 50% of nmCRPC and PSA ≤0.2 in 71% of mHSPC and 39% of nmCRPC. Treatment-related adverse events occurred in 40.1% of mHSPC and 44.4% of nmCRPC. After discontinuation of apalutamide due to disease progression, 54.5% in mHSPC and 75% in nmCRPC started chemotherapy, while after discontinuation because of adverse events, 73.3% in mHSPC and 100% in nmCRPC continued with other hormonal-therapies. Conclusions: The efficacy and safety of apalutamide were similar to that described in the pivotal trials, despite including an older and more comorbid population. Usually, subsequent therapies after apalutamide differed depending on the reason for discontinuation: by disease progression started chemotherapy and by adverse events hormonal sequencing.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Wiley
dc.relation.ispartof Cancer Med. 2023 Dec;12(24):21969-77
dc.rights © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1002/cam4.6769
dc.subject.keyword Apalutamide
dc.subject.keyword High-risk non-metastatic castration-resistant prostate cancer
dc.subject.keyword Metastatic hormone-sensitive prostate cancer
dc.subject.keyword Prostate cancer
dc.subject.keyword Real-world
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking